Qiagen (QGEN) Competitors $46.71 +0.49 (+1.05%) Closing price 03:59 PM EasternExtended Trading$46.72 +0.02 (+0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock QGEN vs. ARGX, BNTX, ONC, TEVA, ITCI, GMAB, SMMT, RDY, ASND, and MRNAShould you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Qiagen vs. Its Competitors argenx BioNTech Beigene Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Qiagen (NYSE:QGEN) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, community ranking, analyst recommendations, valuation, media sentiment and institutional ownership. Does the MarketBeat Community prefer QGEN or ARGX? argenx received 415 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 67.61% of users gave argenx an outperform vote while only 60.19% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes25160.19% Underperform Votes16639.81% argenxOutperform Votes66667.61% Underperform Votes31932.39% Do analysts prefer QGEN or ARGX? Qiagen currently has a consensus price target of $48.42, indicating a potential upside of 3.66%. argenx has a consensus price target of $709.18, indicating a potential upside of 23.34%. Given argenx's stronger consensus rating and higher possible upside, analysts plainly believe argenx is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30argenx 0 Sell rating(s) 1 Hold rating(s) 19 Buy rating(s) 2 Strong Buy rating(s) 3.05 Which has more risk and volatility, QGEN or ARGX? Qiagen has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Which has stronger valuation and earnings, QGEN or ARGX? Qiagen has higher earnings, but lower revenue than argenx. argenx is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$2.00B5.18$83.59M$0.40116.77argenx$2.58B13.61-$295.05M$16.2135.47 Is QGEN or ARGX more profitable? Qiagen has a net margin of 4.23% compared to argenx's net margin of -2.11%. Qiagen's return on equity of 13.92% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.23% 13.92% 8.40% argenx -2.11%-1.45%-1.29% Does the media prefer QGEN or ARGX? In the previous week, argenx had 3 more articles in the media than Qiagen. MarketBeat recorded 10 mentions for argenx and 7 mentions for Qiagen. argenx's average media sentiment score of 0.78 beat Qiagen's score of 0.66 indicating that argenx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenx 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of QGEN or ARGX? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Summaryargenx beats Qiagen on 11 of the 19 factors compared between the two stocks. Get Qiagen News Delivered to You Automatically Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QGEN vs. The Competition Export to ExcelMetricQiagenBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$10.38B$3.09B$5.57B$19.80BDividend Yield0.59%1.58%5.28%3.84%P/E Ratio130.0533.3227.1735.67Price / Sales5.18469.84409.7246.74Price / Cash12.01168.6838.2517.52Price / Book2.903.457.064.84Net Income$83.59M-$72.35M$3.23B$1.02B7 Day Performance2.11%6.16%2.68%1.90%1 Month Performance11.55%20.42%12.02%5.49%1 Year Performance9.23%-17.03%31.24%10.62% Qiagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QGENQiagen3.169 of 5 stars$46.71+1.1%$48.42+3.7%+6.0%$10.38B$2.00B130.056,030ARGXargenx3.5039 of 5 stars$584.60+2.0%$709.18+21.3%+51.7%$35.70B$2.58B-664.32650Analyst ForecastBNTXBioNTech2.8468 of 5 stars$113.10+18.0%$140.14+23.9%+9.1%$27.19B$2.75B-53.863,080Analyst RevisionHigh Trading VolumeONCBeigene1.3376 of 5 stars$245.93+0.1%$319.00+29.7%N/A$24.41B$4.18B-29.859,000Trending NewsInsider TradeTEVATeva Pharmaceutical Industries4.0894 of 5 stars$17.26+2.8%$24.50+42.0%+4.5%$19.56B$16.62B-11.9036,800ITCIIntra-Cellular Therapies0.9126 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.7465 of 5 stars$21.77+3.9%$39.17+79.9%-18.2%$13.96B$3.12B12.511,660Gap UpSMMTSummit Therapeutics2.954 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700K-63.32110Trending NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.4613 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.5224 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.5161 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending News Related Companies and Tools Related Companies ARGX Alternatives BNTX Alternatives ONC Alternatives TEVA Alternatives ITCI Alternatives GMAB Alternatives SMMT Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:QGEN) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qiagen Please log in to your account or sign up in order to add this asset to your watchlist. Share Qiagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.